Appropriate use of tumour biomarkers for treatment with innovative drugs: A retrospective study

Massa,Ilaria; Nanni,Oriana; Guidoboni,Massimo; Frassineti,Giovanni  Luca; Rocca,Andrea; Burgio,Marco  Angelo; Valmorri,Linda; Marri,Mattia; Piancastelli,Alessandra; Faedi,Marina; Leoni,Maurizio; Tamberi,Stefano; Altini,Mattia; Amadori,Dino

doi:10.3892/ol.2015.3967

January-2016 Volume 11 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

January-2016 Volume 11 Issue 1

Full Size Image

Article

Appropriate use of tumour biomarkers for treatment with innovative drugs: A retrospective study

Authors:
- Ilaria Massa
- Oriana Nanni
- Massimo Guidoboni
- Giovanni Luca Frassineti
- Andrea Rocca
- Marco Angelo Burgio
- Linda Valmorri
- Mattia Marri
- Alessandra Piancastelli
- Marina Faedi
- Maurizio Leoni
- Stefano Tamberi
- Mattia Altini
- Dino Amadori
View Affiliations / Copyright

Affiliations: Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola 47014, Italy, Immunotherapy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola 47014, Italy, Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola 47014, Italy, Oncology Unit, Santa Maria delle Croci Hospital, Ravenna 48121, Italy, Oncology Unit, Degli Infermi Hospital, Faenza 48018, Italy, Healthcare Administration, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola 47014, Italy
Pages: 831-836
|
Published online on: November 24, 2015

https://doi.org/10.3892/ol.2015.3967
Expand metrics +

Abstract

Performing randomised clinical trials to address the clinical usefulness of predictive and prognostic tumour markers is a complex process for several reasons, and observational experiences may thus play an important role. The present study performed an observational retrospective analysis in Area Vasta Romagna, Italy, collecting information on tumour marker determination in 760 consecutive patients who started a new line of anticancer therapy between January and June 2010. The determination of well‑known biomarkers was requested for all gastrointestinal stromal tumour (GIST) patients (n=13) and for almost all breast cancer patients (n=369), and targeted therapies were consequently prescribed. Conversely, Kirsten rat sarcoma viral oncogene homolog (KRAS) determination in colon cancer patients (n=177) was requested in ~50% of advanced cases, while epidermal growth factor receptor (EGFR) determination was required in slightly more than 30% of the same patients. EGFR and KRAS determinations were requested in only 15% and 7.5% of non‑small cell lung cancer (NSCLC) patients (n=201), respectively. There would appear to be greater appropriateness of tumour marker determination for breast cancer and GISTs than for colon cancer and NSCLC. Resources can be further optimised by standardising tumour marker determinations in terms of the timing of requests and the consequent use of the results for tailored treatment planning.

View Figures

View References

1	McShane LM and Hayes DF: Publication of tumor marker research results: The necessity for complete and transparent reporting. J Clin Oncol. 30:4223–4232. 2012. View Article : Google Scholar : PubMed/NCBI
2	Henry NL and Hayes DF: Cancer biomarkers. Mol Oncol. 6:140–146. 2012. View Article : Google Scholar : PubMed/NCBI
3	NCCN: Clinical Practice Guidelines in Oncology. Breast Cancer Screening and Diagnosis. V.1.2010. http://www.nccn.org/professionals/physician_gls/f_guidelines.aspAccessed. November 15–2014
4	NCCN: Clinical Practice Guidelines in Oncology. Colon cancer. V.I.2010. http://www.nccn.org/professionals/physician_gls/f_guidelines.aspAccessed. November 15–2014
5	NCCN: Clinical Practice Guidelines in Oncology. Non small lung cell cancer. V.2.2010. http://www.nccn.org/professionals/physician_gls/f_guidelines.aspAccessed. November 15–2014
6	Scottish Intercollegiate Guidelines Network: SIGN Guidelines. http://www.sign.ac.uk/guidelines/published/Accessed. November 15–2014
7	Azzoli CG, Temin S, Aliff T, et al: 2011 Focused update of 2009 American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 29:3825–3831. 2011. View Article : Google Scholar : PubMed/NCBI
8	Harris L, Fritsche H, Mennel R, et al: American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 25:5287–5312. 2007. View Article : Google Scholar : PubMed/NCBI
9	EMEA: Reflection paper on pharmacogenomics in oncology-draft guideline. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003866.pdfAccessed. November 15–2014
10	ESMO: Clinical Practice Guidelines. http://www.esmo.org/GuidelinesAccessed. November 15–2014
11	AIOM: Clinical Guidelines. http://www.aiom.it/Accessed. November 15–2014
12	SIAPEC-IAP: Guidelines. https://www.siapec.itAccessed. November 15–2014
13	Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 359:1757–1765. 2008. View Article : Google Scholar : PubMed/NCBI
14	Cohen M, Williams GA, Sridhara R, et al: United States food and drug administration approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res. 10:1212–1218. 2004. View Article : Google Scholar : PubMed/NCBI
15	Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
16	Scartozzi M, Bearzi I, Berardi R, et al: Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: Implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol. 22:4772–4778. 2004. View Article : Google Scholar : PubMed/NCBI
17	de Castro-Carpeño J, Belda-Iniesta C, Casado Sáenz E, et al: EGFR and colon cancer: A clinical view. Clin Transl Oncol. 10:6–13. 2008. View Article : Google Scholar : PubMed/NCBI
18	Atkins D, Best D, Briss PA, et al: Grading quality of evidence and strength of recommendations. BMJ. 328:14902004. View Article : Google Scholar : PubMed/NCBI
19	Patel JD, Krilov L, Adams S, et al: Clinical cancer advances 2013: Annual report on progress against cancer from the American society of clinical oncology. J Clin Oncol. 32:129–160. 2014. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Appropriate use of tumour biomarkers for treatment with innovative drugs: A retrospective study

This article is mentioned in:

Abstract

Related Articles